Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review

Neuroscience and Biobehavioral Reviews

Volumn 53, Issue , 2015, Pages 108-120

  Cheung, Yin Ting ^a   Krull, Kevin R ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Cancer survivorship; Chemotherapy; Neurocognitive; Pediatric cancer

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; HYDROCORTISONE; METHOTREXATE; NEUROFILAMENT PROTEIN; NEURON SPECIFIC ENOLASE; PREDNISONE; TAU PROTEIN; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ATTENTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVOR; CHILD; CHILDHOOD LEUKEMIA; COGNITIVE DEFECT; DRUG MEGADOSE; EXECUTIVE FUNCTION; GENE INTERACTION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MEMORY; MOTOR PERFORMANCE; NEUROCOGNITIVE IMPAIRMENT; NEUROLOGIC DISEASE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SYSTEMATIC REVIEW; COGNITION; DRUG EFFECTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PSYCHOLOGY; SURVIVOR;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; COGNITION; HUMANS; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVORS;

EID: 84927664690     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.03.016     Document Type: Review

References (103)

1. Aukema E.J., Caan M.W.A., Oudhuis N., et al. White matter fractional anisotropy correlates with speed of processing and motor speed in young childhood cancer survivors. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74(3):837-843.
2. Badr H., Chandra J., Paxton R.J., et al. Health-related quality of life, lifestyle behaviors, and intervention preferences of survivors of childhood cancer. J. Cancer Surviv. 2013, 7(4):523-534.
3. Banerjee T.D., Middleton F., Faraone S.V. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr. 2007, 96(9):1269-1274.
4. Barrett J.S., Patel D., Dombrowsky E., et al. Risk assessment of drug interaction potential and concomitant dosing pattern on targeted toxicities in pediatric cancer patients. AAPS J. 2013, 15(3):775-786.
5. Bhojwani D., Sabin N.D., Pei D., et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 2014, 32(9):949-959.
6. Brinkman T.M., Zhu L., Zeltzer L.K., et al. Longitudinal patterns of psychological distress in adult survivors of childhood cancer. Br. J. Cancer 2013, 109(5):1373-1381.
7. Buizer A.I., De Sonneville L.M.J., Van Den Heuvel-Eibrink M.M., et al. Visuomotor control in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. J. Int. Neuropsychol. Soc. 2005, 11(5):554-565.
8. Caron J.E., Krull K.R., Hockenberry M., et al. Oxidative stress and executive function in children receiving chemotherapy for acute lymphoblastic leukemia. Pediatr. Blood Cancer 2009, 53(4):551-556.
9. Castaldo P., Magi S., Nasti A.A., et al. Clinical pharmacogenetics of methotrexate. Curr. Drug Metab. 2011, 12(3):278-286.
10. Clanton N.R., Klosky J.L., Li C., et al. Fatigue, vitality, sleep, and neurocognitive functioning in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer 2011, 117(11):2559-2568.
11. COG The Children's Oncology Group: Protocols 2015, http://www.childrensoncologygroup.org/ (retrieved 26.02.15).
12. Conklin H.M., Krull K.R., Reddick W.E., et al. Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J. Natl. Cancer Inst. 2012, 104(18):1386-1395.
13. Daams M., Schuitema I., van Dijk B.W., et al. Long-term effects of cranial irradiation and intrathecal chemotherapy in treatment of childhood leukemia: a MEG study of power spectrum and correlated cognitive dysfunction. BMC Neurol. 2012, 12:84.
14. De Sonneville L.M.J. Amsterdam neuropsychological tasks: a computer-aided assessment program. Cognitive Ergonomics, Clinical Assessment, and Computer-Assisted Learning 1999, Swets and Zeitlinger, Lisse, The Netherlands. B.P. Den Brinker, P.J. Beek, A.N. Brand (Eds.).
15. Delis D.C., Kaplan E., Kramer J.H. Delis-Kaplan Executive Function System 2001, Psychological Corporation, San Antonio, TX.
16. Drozdowicz L.B., Bostwick J.M. Psychiatric adverse effects of pediatric corticosteroid use. Mayo Clin. Proc. 2014, 89(6):817-834.
17. Edelmann M.N., Krull K.R., Liu W., et al. Diffusion tensor imaging and neurocognition in survivors of childhood acute lymphoblastic leukaemia. Brain 2014, 137(11):2973-2983.
18. Edelmann M.N., Ogg R.J., Scoggins M.A., et al. Dexamethasone exposure and memory function in adult survivors of childhood acute lymphoblastic leukemia: a report from the SJLIFE cohort. Pediatr. Blood Cancer 2013, 60(11):1778-1784.
19. Egbelakin A., Ferguson M.J., MacGill E.A., et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr. Blood Cancer 2011, 56(3):361-367.
20. Elalfy M., Ragab I., Azab I., et al. Neurocognitive outcome and white matter anisotropy in childhood acute lymphoblastic leukemia survivors treated with different protocols. Pediatr. Hematol. Oncol. 2014, 31(2):194-204.
21. Essig S., Li Q., Chen Y., et al. Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2014, 15(8):841-851.
22. Feig S.A., Gamis A.S., Hord J.D., et al. Long-term follow-up care for pediatric cancer survivors. Pediatrics 2009, 123(3):906-915.
23. Firoozi M., Besharat M.A., Boogar E.R. Emotional regulation and adjustment to childhood cancer: role of the biological, psychological and social regulators on pediatric oncology adjustment. Iran. J. Cancer Prev. 2013, 6(2):65-72.
24. Fleury I., Primeau M., Doreau A., et al. Polymorphisms in genes involved in the corticosteroid response and the outcome of childhood acute lymphoblastic leukemia. Am. J. Pharmacogenomics 2004, 4(5):331-341.
25. Gaynon P.S., Angiolillo A.L., Carroll W.L., et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a children's oncology group report. Leukemia 2010, 24(2):285-297.
26. Genschaft M., Huebner T., Plessow F., et al. Impact of chemotherapy for childhood leukemia on brain morphology and function. PLOS ONE 2013, 8(11):e78599.
27. Gilbody S., Lewis S., Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am. J. Epidemiol. 2007, 165(1):1-13.
28. Gokcen C., Kocak N., Pekgor A. Methylenetetrahydrofolate reductase gene polymorphisms in children with attention deficit hyperactivity disorder. Int. J. Med. Sci. 2011, 8(7):523-528.
29. Gordijn M.S., van Litsenburg R.R., Gemke R.J., et al. Sleep, fatigue, depression, and quality of life in survivors of childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer 2013, 60(3):479-485.
30. Haidar C., Jeha S. Drug interactions in childhood cancer. Lancet Oncol. 2011, 12(1):92-99.
31. Halsey C., Buck G., Richards S., et al. The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. J. Hematol. Oncol. 2011, 4:42.
32. Harila M.J., Winqvist S., Lanning M., et al. Progressive neurocognitive impairment in young adult survivors of childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer 2009, 53(2):156-161.
33. Hartman A., Hop W., Takken T., et al. Motor performance and functional exercise capacity in survivors of pediatric acute lymphoblastic leukemia. Pediatr. Blood Cancer 2013, 60(3):494-499.
34. Hicks B.M., Dirago A.C., Iacono W.G., et al. Gene-environment interplay in internalizing disorders: consistent findings across six environmental risk factors. J. Child Psychol. Psychiatry Allied Discipl. 2009, 50(10):1309-1317.
35. Hill D.E., Ciesielski K.T., Hart B.L., et al. MRI morphometric and neuropsychological correlates of long-term memory in survivors of childhood leukemia. Pediatr. Blood Cancer 2004, 42(7):611-617.
36. Huang I.C., Brinkman T.M., Kenzik K., et al. Association between the prevalence of symptoms and health-related quality of life in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study. J. Clin. Oncol. 2013, 31(33):4242-4251.
37. Hudson M.M., Ness K.K., Gurney J.G., et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. J. Am. Med. Assoc. 2013, 309(22):2371-2381.
38. Jabbour E., O'Brien S., Kantarjian H., et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007, 109(8):3214-3218.
39. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat. Rev. 2010, 36(4):277-285.
40. Kadan-Lottick N.S., Brouwers P., Breiger D., et al. A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood 2009, 114(9):1746-1752.
41. Kadan-Lottick N.S., Zeltzer L.K., Liu Q., et al. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J. Natl. Cancer Inst. 2010, 102(12):881-893.
42. Kingma A., Van Dommelen R.I., Mooyaart E.L., et al. Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J. Pediatr. 2001, 139(3):413-420.
43. Kishi S., Griener J., Cheng C., et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J. Clin. Oncol. 2003, 21(16):3084-3091.
44. Krajinovic M., Robaey P., Chiasson S., et al. Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics 2005, 6(3):293-302.
45. Krappmann P., Paulides M., Stöhr W., et al. Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up. Pediatr. Hematol. Oncol. 2007, 24(2):101-109.
46. Krawczuk-Rybak M., Grabowska A., Protas P.T., et al. Intellectual functioning of childhood leukemia survivors - relation to Tau protein - a marker of white matter injury. Adv. Med. Sci. 2012, 57(2):266-272.
47. Krull K.R., Bhojwani D., Conklin H.M., et al. Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 2013, 31(17):2182-2188.
48. Krull K.R., Brinkman T.M., Li C., et al. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St. Jude Lifetime Cohort Study. J. Clin. Oncol. 2013, 31(35):4407-4415.
49. Krull K.R., Khan R.B., Ness K.K., et al. Symptoms of attention-deficit/hyperactivity disorder in long-term survivors of childhood leukemia. Pediatr. Blood Cancer 2011, 57(7):1191-1196.
50. Krull K.R., Sabin N.D., Reddick W.E., et al. Neurocognitive function and CNS integrity in adult survivors of childhood Hodgkin lymphoma. J. Clin. Oncol. 2012, 30(29):3618-3624.
51. Landier W., Bhatia S., Eshelman D.A., et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J. Clin. Oncol. 2004, 22(24):4979-4990.
52. Langer T., Martus P., Ottensmeier H., et al. CNS late-effects after ALL therapy in childhood: Part III. Neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. Med. Pediatr. Oncol. 2002, 38(5):320-328.
53. Lewis F.M., Perry M.L., Murdoch B.E. Longitudinal language outcomes following intrathecal chemotherapy for acute lymphoblastic leukaemia. Int. J. Speech Lang. Pathol. 2013, 15(2):156-164.
54. Lewis F.M., Su I.F., Murdoch B.E. Indices of language outcome 11 years after intrathecal chemotherapy for acute lymphoblastic leukemia: a sibling case-control study. Pediatr. Hematol. Oncol. 2012, 29(2):176-190.
55. Long K.A., Keeley L., Reiter-Purtill J., et al. Child-rearing in the context of childhood cancer: perspectives of parents and professionals. Pediatr. Blood Cancer 2014, 61(2):326-332.
56. Lund L.W., Schmiegelow K., Rechnitzer C., et al. A systematic review of studies on psychosocial late effects of childhood cancer: structures of society and methodological pitfalls may challenge the conclusions. Pediatr. Blood Cancer 2011, 56(4):532-543.
57. Mahone E.M., Prahme M.C., Ruble K., et al. Motor and perceptual timing deficits among survivors of childhood leukemia. J. Pediatr. Psychol. 2007, 32(8):918-925.
58. Manuck S.B., McCaffery J.M. Gene-environment interaction. Annu. Rev. Psychol. 2014, 65:41-70.
59. Marcoux S., Robaey P., Gahier A., et al. Role of NOS3 DNA variants in externalizing behavioral problems observed in childhood leukemia survivors. J. Pediatr. Hematol. Oncol. 2013, 35(4):e157-e162.
60. Massimo L.M., Wiley T.J., Bonassi S., et al. Longitudinal psychosocial outcomes in two cohorts of adult survivors from childhood acute leukemia treated with or without cranial radiation. Miner. Pediatr. 2006, 58(1):1-7.
61. Mazur B., Mertas A., Sońta-Jakimczyk D., et al. Concentration of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia after cessation of chemotherapy. Hematol. Oncol. 2004, 22(1):27-34.
62. Meeske K.A., Siegel S.E., Globe D.R., et al. Prevalence and correlates of fatigue in long-term survivors of childhood leukemia. J. Clin. Oncol. 2005, 23(24):5501-5510.
63. Mulrooney D.A., Ness K.K., Neglia J.P., et al. Fatigue and sleep disturbance in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS). Sleep 2008, 31(2):271-281.
64. Myers R.M., Balsamo L., Lu X., et al. A prospective study of anxiety, depression, and behavioral changes in the first year after a diagnosis of childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Cancer 2014, 120(9):1417-1425.
65. Norberg A.L., Boman K.K. Parent distress in childhood cancer: a comparative evaluation of posttraumatic stress symptoms, depression and anxiety. Acta Oncol. 2008, 47(2):267-274.
66. Octavia Y., Tocchetti C.G., Gabrielson K.L., et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J. Mol. Cell. Cardiol. 2012, 52(6):1213-1225.
67. Österlundh G., Kjellmer I., Lannering B., et al. Neurochemical markers of brain damage in cerebrospinal fluid during induction treatment of acute lymphoblastic leukemia in children. Pediatr. Blood Cancer 2008, 50(4):793-798.
68. Pike A., Iervolino A.C., Eley T.C., et al. Environmental risk and young children's cognitive and behavioral development. Int. J. Behav. Dev. 2006, 30(1):55-66.
69. Pound C.M., Clark C., Ni A., et al. Corticosteroids, behavior, and quality of life in children treated for acute lymphoblastic leukemia: a multicentered trial. J. Pediatr. Hematol. Oncol. 2012, 34(7):517-523.
70. Protas P.T., Holownia A., Muszynska-Roslan K., et al. Cerebrospinal fluid IL-6, TNF-α and MCP-1 in children with acute lymphoblastic leukaemia during chemotherapy. Neuropediatrics 2011, 42(6):254-256.
71. Pui C.H. Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 2003, 21(2):179-181.
72. Pui C.H., Campana D., Pei D., et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 2009, 360(26):2730-2741.
73. Pui C.H., Kane J.R., Crist W.M. Biology and treatment of infant leukemias. Leukemia 1995, 9(5):762-769.
74. Pui C.H., Mahmoud H.H., Rivera G.K., et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 1998, 92(2):411-415.
75. Pui C.H., Sandlund J.T., Pei D., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St. Jude Children's Research Hospital. Blood 2004, 104(9):2690-2696.
76. Quinn C.T., Griener J.C., Bottiglieri T., et al. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J. Clin. Oncol. 1997, 15(8):2800-2806.
77. Reddick W.E., Glass J.O., Helton K.J., et al. Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. Am. J. Neuroradiol. 2005, 26(5):1263-1269.
78. Refsum H., Wesenberg F., Ueland P.M. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res. 1991, 51(3):828-835.
79. Robinson K.E., Livesay K.L., Campbell L.K., et al. Working memory in survivors of childhood acute lymphocytic leukemia: functional neuroimaging analyses. Pediatr. Blood Cancer 2010, 54(4):585-590.
80. Ross C.S., Brown T.M., Kotagal S., et al. Cerebral venous sinus thrombosis in pediatric cancer patients: long-term neurological outcomes. J. Pediatr. Hematol. Oncol. 2013, 35(4):299-302.
81. Ruggiero A., Arena R., Battista A., et al. Azole interactions with multidrug therapy in pediatric oncology. Eur. J. Clin. Pharmacol. 2013, 69(1):1-10.
82. Rühs H., Becker A., Drescher A., et al. Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia. PLoS ONE 2012, 7(9):e46015.
83. Ruzzo E.K., Capo-Chichi J.M., Ben-Zeev B., et al. Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy. Neuron 2013, 80(2):429-441.
84. Saha T., Dutta S., Rajamma U., et al. A pilot study on the contribution of folate gene variants in the cognitive function of ADHD probands. Neurochem. Res. 2014, 39(11):2058-2087.
85. Schuitema I., Deprez S., Van Hecke W., et al. Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies. J. Clin. Oncol. 2013, 31(27):3378-3388.
86. Seruga B., Zhang H., Bernstein L.J., et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer 2008, 8(11):887-899.
87. Simone J.V. History of the treatment of childhood ALL: a paradigm for cancer cure. Best Pract. Res. Clin. Haematol. 2006, 19(2):353-359.
88. Speechley K.N., Barrera M., Shaw A.K., et al. Health-related quality of life among child and adolescent survivors of childhood cancer. J. Clin. Oncol. 2006, 24(16):2536-2543.
89. Spiegler B.J., Kennedy K., Maze R., et al. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J. Clin. Oncol. 2006, 24(24):3858-3864.
90. Stenzel S.L., Krull K.R., Hockenberry M., et al. Oxidative stress and neurobehavioral problems in pediatric acute lymphoblastic leukemia patients undergoing chemotherapy. J. Pediatr. Hematol. Oncol. 2010, 32(2):113-118.
91. Tonorezos E.S., Robien K., Eshelman-Kent D., et al. Contribution of diet and physical activity to metabolic parameters among survivors of childhood leukemia. Cancer Causes Control 2013, 24(2):313-321.
92. Trask C.L., Greene Welch J.J., Manley P., et al. Parental needs for information related to neurocognitive late effects from pediatric cancer and its treatment. Pediatr. Blood Cancer 2009, 52(2):273-279.
93. Tremolada M., Bonichini S., Aloisio D., et al. Post-traumatic stress symptoms among mothers of children with leukemia undergoing treatment: a longitudinal study. Psycho-Oncology 2013, 22(6):1266-1272.
94. Van Norren K., Van Helvoort A., Argilés J.M., et al. Direct effects of doxorubicin on skeletal muscle contribute to fatigue. Br. J. Cancer 2009, 100(2):311-314.
95. van Schie R.M., Brüggemann R.J.M., Hoogerbrugge P.M., et al. Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. J. Antimicrob. Chemother. 2011, 66(8):1853-1856.
96. Von der Weid N. Late effects in long-term survivors of all in childhood: experiences from the SPOG late effects study. Swiss Med. Wkly. 2001, 131(13-14):180-187.
97. Warris L.T., Van den Heuvel-Eibrink M.M., den Hoed M.A.H., et al. Does dexamethasone induce more neuropsychological side effects than prednisone in pediatric acute lymphoblastic leukemia? A systematic review. Pediatr. Blood Cancer 2014, 61(7):1313-1318.
98. Wechsler D. Wechsler Adult Intelligence Scale 1997, Psychological Corporation, San Antonio, TX.
99. Williams L.K., Lamb K.E., McCarthy M.C. Behavioral side effects of pediatric acute lymphoblastic leukemia treatment: the role of parenting strategies. Pediatr. Blood Cancer 2014, 61(11):2065-2070.
100. Williams L.K., McCarthy M.C. Parent perceptions of managing child behavioural side-effects of cancer treatment: a qualitative study. Child 2014, (Epub 28.08.14).
101. Wilson C.J., Finch C.E., Cohen H.J. Cytokines and cognition - the case for a head-to-toe inflammatory paradigm. J. Am. Geriatr. Soc. 2002, 50(12):2041-2056.
102. Woodcock R.W., McGrew K.S., Mather N. Woodcock-Johnson III: Tests of Achievement 2001, Riverside, Itasca, IL.
103. Yang L., Hu X., Xu L. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumor Biol. 2012, 33(5):1445-1454.